Risk Factors for Rituximab-Induced Interstitial Lung Diseases in Patients with Malignant Lymphoma

Publisher： Karger

E-ISSN： 1423-0356|85|2|175-175

ISSN： 0025-7931

Source： Respiration, Vol.85, Iss.2, 2012-12, pp. : 175-175

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

TNF‐α antagonist may not be suitable for severe rituximab‐induced interstitial lung disease

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 3, 2015-06 ,pp. : 249-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab-Induced Hypersensitivity Pneumonitis

By  

Respiration, Vol. 78, Iss. 2, 2008-10 ,pp. : 225-229

Karger

Access to resources Recommend Favorite

Rituximab-Induced Interstitial Pneumonia due to CD8-Positive T Cell Infiltration

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 107-109

Karger

Access to resources Recommend Favorite

Interstitial Lung Diseases: Introduction

By  

Respiration, Vol. 71, Iss. 1, 2004-02 ,pp. : 3-

Karger

Access to resources Recommend Favorite

Induced Sputum in Interstitial Lung Diseases: Novel Insights in the Diagnosis, Evaluation and Research

By  

Respiration, Vol. 77, Iss. 3, 2008-12 ,pp. : 351-358

Karger

Access to resources Recommend Favorite